Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vanda Pharmaceuticals Inc.VNDA · Entity 5861 | SVP, Chief Marketing Officer | March 02, 2026 | March 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vanda Pharmaceuticals Inc.
Report date March 02, 2026 · Filed March 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 333,469 |
Reported balance
After 2026-03-02 transaction · row 1
1 source rowRow 1 · 2026-03-02 · Sale · Disposed 30,800 · Balance 333,469 F1: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to the withholding tax provisions of the RSU agreements. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.085 to $8.81 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to the withholding tax provisions of the RSU agreements.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.085 to $8.81 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 02, 2026 Filed Mar 4, 2026 23:52 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 30,800 | $8.27 | $254,589.72 |
DisclosureSEC source: 0001785888-26-000002 · ownership.xml · nonDerivative · entry 1 Wijkstrom Joakim · CIK 0001785888 · SVP, Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 333,469 F1 · shares: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to the withholding tax provisions of the RSU agreements. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.085 to $8.81 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| February 18, 2026 Filed Feb 19, 2026 22:53 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 125,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-059792 · ownership.xml · nonDerivative · entry 1 Wijkstrom Joakim · CIK 0001785888 · SVP, Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 364,269 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2027, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 21:46 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Tax withholdingCommon Stock | 15,520 | $4.76 | $73,875.20 |
DisclosureSEC source: 0000950170-25-032285 · ownership.xml · nonDerivative · entry 1 Wijkstrom Joakim · CIK 0001785888 · SVP, Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 239,269 F1 · shares: Represents shares of the Issuer's common stock withheld to satisfy tax withholding obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Read SEC document |
| February 18, 2025 Filed Feb 21, 2025 01:21 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 125,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-024498 · ownership.xml · nonDerivative · entry 1 Wijkstrom Joakim · CIK 0001785888 · SVP, Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 254,789 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2026, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. Read SEC document |
| March 05, 2024 Filed Mar 6, 2024 21:48 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 9,229 | $4.21 | $38,830.09 |
DisclosureSEC source: 0000950170-24-027259 · ownership.xml · nonDerivative · entry 2 Wijkstrom Joakim · CIK 0001785888 · SVP, Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,789 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to the default "same day sale" provisions of the RSU agreements. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.2027 to $4.225, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 21:48 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 7,498 | $4.41 | $33,090.92 |
DisclosureSEC source: 0000950170-24-027259 · ownership.xml · nonDerivative · entry 1 Wijkstrom Joakim · CIK 0001785888 · SVP, Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,018 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to the default "same day sale" provisions of the RSU agreements. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.38 to $4.4402, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 21:52 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 32,700 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-018032 · ownership.xml · nonDerivative · entry 1 Wijkstrom Joakim · CIK 0001785888 · SVP, Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,516 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2025, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. Read SEC document |
| August 21, 2023 Filed Aug 23, 2023 20:23 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 3,724 | $5.84 | $21,748.16 |
DisclosureSEC source: 0001209191-23-047056 · doc4.xml · nonDerivative · entry 1 Wijkstrom Joakim · CIK 0001785888 · SVP, Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,816 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. Read SEC document |
| March 03, 2023 Filed Mar 6, 2023 23:26 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 4,113 | $6.32 | $25,994.16 |
DisclosureSEC source: 0001209191-23-016463 · doc4.xml · nonDerivative · entry 2 Wijkstrom Joakim · CIK 0001785888 · SVP, Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,540 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 23:26 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 7,720 | $6.23 | $48,122.62 |
DisclosureSEC source: 0001209191-23-016463 · doc4.xml · nonDerivative · entry 1 Wijkstrom Joakim · CIK 0001785888 · SVP, Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,653 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.2201 to $6.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:11 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantStock Option (Right to Buy) · Derivative | 77,500 | $0.00 Strike: $7.05 | $0.00 |
DisclosureSEC source: 0001209191-23-011342 · doc4.xml · derivative · entry 2 Wijkstrom Joakim · CIK 0001785888 · SVP, Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,500 Underlying: Common Stock · 77,500 shares Expires 2033-02-15 F2 · derivative.exercise_date: The option vests with respect to 25% of the underlying shares on February 16, 2024, with the balance vesting in equal monthly installments over the next 36 months of continuous service thereafter, provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:11 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 32,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-011342 · doc4.xml · nonDerivative · entry 1 Wijkstrom Joakim · CIK 0001785888 · SVP, Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,373 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2024, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. Read SEC document |
| August 22, 2022 Filed Aug 23, 2022 21:01 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 3,605 | $10.27 | $37,007.49 |
DisclosureSEC source: 0001209191-22-047210 · doc4.xml · nonDerivative · entry 1 Wijkstrom Joakim · CIK 0001785888 · SVP, Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,673 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. Read SEC document |
| March 02, 2022 Filed Mar 3, 2022 02:28 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 6,974 | $11.19 | $78,059.98 |
DisclosureSEC source: 0001209191-22-015158 · doc4.xml · nonDerivative · entry 2 Wijkstrom Joakim · CIK 0001785888 · SVP, Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,278 F2 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.15 to $11.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 02:28 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantStock Option (Right to Buy) · Derivative | 77,500 | $0.00 Strike: $11.36 | $0.00 |
DisclosureSEC source: 0001209191-22-015158 · doc4.xml · derivative · entry 3 Wijkstrom Joakim · CIK 0001785888 · SVP, Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,500 Underlying: Common Stock · 77,500 shares Expires 2032-02-27 F4 · derivative.exercise_date: The option vests with respect to 25% of the underlying shares on February 28, 2023, with the balance vesting in equal monthly installments over the next 36 months of continuous service thereafter, provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date. Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 02:28 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 32,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-015158 · doc4.xml · nonDerivative · entry 1 Wijkstrom Joakim · CIK 0001785888 · SVP, Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,252 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2023, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. Read SEC document |
| August 20, 2021 Filed Aug 23, 2021 20:36 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 3,650 | $15.39 | $56,189.56 |
DisclosureSEC source: 0001209191-21-052965 · doc4.xml · nonDerivative · entry 1 Wijkstrom Joakim · CIK 0001785888 · SVP, Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,552 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.30 to $15.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| March 02, 2021 Filed Mar 3, 2021 23:42 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 3,888 | $18.45 | $71,728.93 |
DisclosureSEC source: 0001209191-21-017278 · doc4.xml · nonDerivative · entry 1 Wijkstrom Joakim · CIK 0001785888 · SVP, Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,202 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.37 to $18.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 22:19 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantEmployee Stock Option (Right to Buy) · Derivative | 61,200 | $0.00 Strike: $20.28 | $0.00 |
DisclosureSEC source: 0001209191-21-014882 · doc4.xml · derivative · entry 2 Wijkstrom Joakim · CIK 0001785888 · SVP, Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,200 Underlying: Common Stock · 61,200 shares Expires 2031-02-23 F2 · derivative.exercise_date: The option vests with respect to 25% of the underlying shares on February 24, 2022, with the balance vesting in equal monthly installments over the next 36 months of continuous service thereafter, provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 22:19 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 25,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-014882 · doc4.xml · nonDerivative · entry 1 Wijkstrom Joakim · CIK 0001785888 · SVP, Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,090 F1 · price: Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. Read SEC document |
| August 20, 2020 Filed Aug 21, 2020 22:08 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 3,710 | $11.08 | $41,109.03 |
DisclosureSEC source: 0001209191-20-047991 · doc4.xml · nonDerivative · entry 1 Wijkstrom Joakim · CIK 0001785888 · SVP, Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,290 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.08 to $11.095, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 23:04 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantEmployee Stock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $11.32 | $0.00 |
DisclosureSEC source: 0001209191-20-014129 · doc4.xml · derivative · entry 2 Wijkstrom Joakim · CIK 0001785888 · SVP, Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2030-02-25 F2 · derivative.exercise_date: The option vests with respect to 25% of the underlying shares on February 26, 2021, with the balance vesting in equal monthly installments over the next 36 months of continuous service thereafter, provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 23:04 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 30,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-014129 · doc4.xml · nonDerivative · entry 1 Wijkstrom Joakim · CIK 0001785888 · SVP, Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 F1 · price: Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2021, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. Read SEC document |
| August 19, 2019 Filed Aug 21, 2019 20:52 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $15.33 | $0.00 |
DisclosureSEC source: 0001209191-19-047009 · doc4.xml · derivative · entry 2 Wijkstrom Joakim · CIK 0001785888 · SVP, Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2029-08-18 F2 · derivative.exercise_date: The option vests and becomes exercisable with respect to 1/4 of the shares subject to the option on August 19, 2020 (the "Initial Vesting Date"), provided the Reporting Person remains continuously employed by the issuer through the Initial Vesting Date, and with respect to the remaining 3/4 of the shares in 36 equal monthly installments beginning September 19, 2020, provided the Reporting Person remains continuously employed by the issuer through each monthly vesting date. Read SEC document |
| August 19, 2019 Filed Aug 21, 2019 20:52 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 30,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-047009 · doc4.xml · nonDerivative · entry 1 Wijkstrom Joakim · CIK 0001785888 · SVP, Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F1 · price: Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments beginning August 19, 2020, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.